Hypnotic

WikiDoc Resources for Hypnotic
Articles
Most recent articles on Hypnotic Most cited articles on Hypnotic Review articles on Hypnotic Articles on Hypnotic in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hypnotic Images of Hypnotic Photos of Hypnotic Podcasts & MP3s on Hypnotic Videos on Hypnotic
Evidence Based Medicine
Cochrane Collaboration on Hypnotic Bandolier on Hypnotic TRIP on Hypnotic
Clinical Trials
Ongoing Trials on Hypnotic at Clinical Trials.gov Trial results on Hypnotic Clinical Trials on Hypnotic at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hypnotic NICE Guidance on Hypnotic NHS PRODIGY Guidance FDA on Hypnotic CDC on Hypnotic
Books
Books on Hypnotic
News
Hypnotic in the news Be alerted to news on Hypnotic News trends on Hypnotic
Commentary
Blogs on Hypnotic
Definitions
Definitions of Hypnotic
Patient Resources / Community
Patient resources on Hypnotic Discussion groups on Hypnotic Patient Handouts on Hypnotic Directions to Hospitals Treating Hypnotic Risk calculators and risk factors for Hypnotic
Healthcare Provider Resources
Symptoms of Hypnotic Causes & Risk Factors for Hypnotic Diagnostic studies for Hypnotic Treatment of Hypnotic
Continuing Medical Education (CME)
CME Programs on Hypnotic
International
Hypnotic en Espanol Hypnotic en Francais
Business
Hypnotic in the Marketplace Patents on Hypnotic
Experimental / Informatics
List of terms related to Hypnotic

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Overview

Hypnotic drugs are a class of drugs that induce sleep (which differentiates them from the sedative category), used in the treatment of insomnia and in surgical anesthesia. Often the treatment of insomnia will not begin with drugs at all. Because many hypnotic drugs are habit-forming, a physician will usually recommend alternative sleeping patterns and exercise before prescribing medication for sleep. This is due to a large number of factors known to disturb the human sleep pattern.

These drugs include barbiturates, opioids, benzodiazepines (not all, hypnotic benzodiazepines are usually more powerful than the others in their group), zolpidem, zaleplon, zopiclone, eszopiclone, chloral hydrate, chlormethiazole or the antihistamines doxylamine, promethazine, and diphenhydramine. Alcohol is also used as a hypnotic drug.

Hypnotic Withdrawal

Differential Diagnosis

• Alcohol withdrawal
• Anxiety disorders
• Essential tremor
• Hypoglycemia
• Diabetic ketoacidosis
• Seizure due to infections, head injury, poisonings

DSM-V Diagnostic Criteria for Sedative, Hypnotic, or Anxiolytic Withdrawal

“

A. Cessation of (or reduction in) sedative, hypnotic, or anxiolytic use that has been prolonged. AND B. Two (or more) of the following, developing within several hours to a few days after the cessation of (or reduction in) sedative, hypnotic, or anxiolytic use described in Criterion A: 1. Autonomic hyperactivity (e.g., sweating or pulse rate greater than 100 bpm). 2. Hand tremor. 3. Insomnia. 4. Nausea or vomiting. 5. Transient visual, tactile, or auditory hallucinations or illusions. 6. Psychomotor agitation. 7. Anxiety. 8. Grand mal seizures. AND C. The signs or symptoms in Criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. AND D. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication or withdrawal from another substance. Specify if: With perceptual disturbances: This specifier may be noted when hallucinations with intact reality testing or auditory, visual, or tactile illusions occur in the absence of a delirium.

”

Hypnotic Intoxication

Differential Diagnosis

• Alcohol use disorders
• Alcohol intoxication
• Delirium
• Traumatic brain injury

DSM-V Diagnostic Criteria for Sedative, Hypnotic, or Anxiolytic Intoxication

“

A. Recent use of a sedative, hypnotic, or anxiolytic. AND B. Clinically significant maladaptive behavioral or psychological changes (e.g., inappropriate sexual or aggressive behavior, mood lability, impaired judgment) that developed during, or shortly after, sedative, hypnotic, or anxiolytic use. AND C. One (or more) of the following signs or symptoms developing during, or shortly after,sedative, hypnotic, or anxiolytic use: 1. Slurred speech. 2. Incoordination. 3. Unsteady gait. 4. Nystagmus. 5. Impairment in cognition (e.g., attention, memory). 6. Stupor or coma. AND D. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication with another substance.

”

Hypnotic Use Disorder

Differential Diagnosis

• Alcohol use disorder
• Clinically appropriate use of the medication
• Generalized anxiety disorder
• Multiple sclerosis
• Subdural hematoma

Epidemiology and Demographics of Sedative, Hypnotic, or Anxiolytic Use Disorder

Prevalence

The 12 month prevalence of hypnotic or anxiolytic use disorder is:

• 300 per 100,000 (0.3%) among adults 12-17 years old
• 200 per 100,000 among adults 18 years and older

Risk Factors

• Availability of the substances
• Alcohol use disorder
• Environmental factors
• Early onset of use
• Genetic predisposition
• Peer use of the substance

DSM-V Diagnostic Criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder

“

A. A problematic pattern of sedative, hypnotic, or anxiolytic use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period: 1. Sedatives, hypnotics, or anxiolytics are often taken in larger amounts or over a longer period than was intended. 2. There is a persistent desire or unsuccessful efforts to cut down or control sedative, hypnotic, or anxiolytic use. 3. A great deal of time is spent in activities necessary to obtain the sedative, hypnotic,or anxiolytic; use the sedative, hypnotic, or anxiolytic; or recover from its effects. 4. Craving, or a strong desire or urge to use the sedative, hypnotic, or anxiolytic. 5. Recurrent sedative, hypnotic, or anxiolytic use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences from work or poor work performance related to sedative, hypnotic, or anxiolytic use; sedative-,hypnotic-, or anxiolytic-related absences, suspensions, or expulsions from school;neglect of children or household). 6. Continued sedative, hypnotic, or anxiolytic use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of sedatives, hypnotics, or anxiolytics (e.g., arguments with a spouse about consequences of intoxication; physical fights). 7. Important social, occupational, or recreational activities are given up or reduced because of sedative, hypnotic, or anxiolytic use. 8. Recurrent sedative, hypnotic, or anxiolytic use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by sedative, hypnotic, or anxiolytic use). 9. Sedative, hypnotic, or anxiolytic use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the sedative, hypnotic, or anxiolytic. 10. Tolerance, as defined by either of the following; a. A need for markedly increased amounts of the sedative, hypnotic, or anxiolytic to achieve intoxication or desired effect. b. A markedly diminished effect with continued use of the same amount of the sedative,hypnotic, or anxiolytic. Note: This criterion is not considered to be met for individuals taking sedatives, hypnotics, or anxiolytics under medical supervision. 11. Withdrawal, as manifested by either of the following: a. The characteristic withdrawal syndrome for sedatives, hypnotics, or anxiolytics. b. Sedatives, hypnotics, or anxiolytics (or a closely related substance, such as alcohol)are taken to relieve or avoid withdrawal symptoms. Note: This criterion is not considered to be met for individuals taking sedatives, hypnotics, or anxiolytics under medical supervision. Specify if: In early remission: After full criteria for sedative, hypnotic, or anxiolytic use disorder were previously met, none of the criteria for sedative, hypnotic, or anxiolytic use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the sedative, hypnotic, or anxiolytic,” may be met). In sustained remission: After full criteria for sedative, hypnotic, or anxiolytic use disorder were previously met, none of the criteria for sedative, hypnotic, or anxiolytic use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the sedative, hypnotic, or anxiolytic,” may be met). Specify if: In a controlled environment: This additional specifier is used if the individual is in an environment where access to sedatives, hypnotics, or anxiolytics is restricted.

”